Advice

in the absence of a submission from the holder of the marketing authorisation:

corifollitropin alfa (Elonva ®) is not recommended for use within NHSScotland for the treatment of Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice46KB (PDF)

Download

Medicine details

Medicine name:
corifollitropin alfa (Elonva)
SMC ID:
633/10
Indication:
for the treatment of Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program.
Pharmaceutical company
MSD
BNF chapter
Endocrine system
Submission type
Non submission
Status
Not recommended
Date advice published
12 July 2010